SRD5A3-CDG: A Patient with a Novel Variant and Brain Neoplasm.

Cigdem Seher Kasapkara, Asburce Olgac, Betul Emine Derinkuyu, Ulkuhan Oztoprak, Jaak Jaeken

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2022 Dec

filter terms:

Congenital disorders of glycosylation (CDGs) are a large group of genetic diseases with impaired glycosylation of glycoproteins and glycolipids, and glycosylphosphatidylinositol anchor synthesis. Steroid 5α-reductase 3 (SRD5A3)-CDG is a CDG type I with a clinical spectrum of neurological, ophthalmological, dermatological and hepatic symptoms. Although CDGs are not directly related to malignancies, it is well known that some genes that are involved in glycosylation pathways are involved in various cancers. Aberrant glycosylation has been closely linked to the development and progression of brain cancer. We report a patient with SRD5A3-CDG carrying a novel homozygous splice variant and brain neoplasm. Also, a review of the literature is made regarding the multisystem effects of the disease. Key Words: SRD5A3-CDG, Glioma, Glycosylation, Transferrin isoelectric focusing, Congenital disorders of glycosylation.

Citation

Cigdem Seher Kasapkara, Asburce Olgac, Betul Emine Derinkuyu, Ulkuhan Oztoprak, Jaak Jaeken. SRD5A3-CDG: A Patient with a Novel Variant and Brain Neoplasm. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2022 Dec;32(12):SS221-SS226